Including quantitative descriptions and information about serious adverse effects in direct-to-consumer (DTC) ads for a fictional Alzheimer’s medication heightened patients’ apprehensions about the drug, a new survey in JAMA Network Open shows, suggesting regulators may wish to begin requiring ads for these medicines to prominently display this information.